Kiadis Pharma B.V. , a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces that it has initiated a collaboration to identify and characterize leukemia-specific T-cells in Kiadis Pharma's lead product ATIR[TM], that would be responsible for the Graft-versus-Leukemia effect of the T-cell immunotherapy ... (more)
http://ift.tt/1jHsIRL
http://ift.tt/1jHsIRL
No comments:
Post a Comment